Find Maribavir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 176161-24-3, Benzimidavir, 1263w94, Livtencity, (2s,3s,4r,5s)-2-(5,6-dichloro-2-(isopropylamino)-1h-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, Camvia
Molecular Formula
C15H19Cl2N3O4
Molecular Weight
376.2  g/mol
InChI Key
KJFBVJALEQWJBS-XUXIUFHCSA-N
FDA UNII
PTB4X93HE1

Maribavir
Maribavir is an orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents.
Maribavir is a Cytomegalovirus pUL97 Kinase Inhibitor. The mechanism of action of maribavir is as a Cytomegalovirus pUL97 Kinase Inhibitor, and Cytochrome P450 3A4 Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
1 2D Structure

Maribavir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S,3S,4R,5S)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol
2.1.2 InChI
InChI=1S/C15H19Cl2N3O4/c1-6(2)18-15-19-9-3-7(16)8(17)4-10(9)20(15)14-13(23)12(22)11(5-21)24-14/h3-4,6,11-14,21-23H,5H2,1-2H3,(H,18,19)/t11-,12-,13-,14-/m0/s1
2.1.3 InChI Key
KJFBVJALEQWJBS-XUXIUFHCSA-N
2.1.4 Canonical SMILES
CC(C)NC1=NC2=CC(=C(C=C2N1C3C(C(C(O3)CO)O)O)Cl)Cl
2.1.5 Isomeric SMILES
CC(C)NC1=NC2=CC(=C(C=C2N1[C@@H]3[C@H]([C@H]([C@@H](O3)CO)O)O)Cl)Cl
2.2 Other Identifiers
2.2.1 UNII
PTB4X93HE1
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1263-w-94

2. 1263w94

3. 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosylbenzimidazole

4. Benzimidavir

5. Bw 1263w94

6. Bw-1263w94

7. Gw 1263

8. Gw 257406x

9. Gw-1263

10. Gw-257406x

11. Gw257406x

2.3.2 Depositor-Supplied Synonyms

1. 176161-24-3

2. Benzimidavir

3. 1263w94

4. Livtencity

5. (2s,3s,4r,5s)-2-(5,6-dichloro-2-(isopropylamino)-1h-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

6. Camvia

7. Bw-1263w94

8. Gw-257406x

9. Gw-1263

10. Ptb4x93he1

11. (2s,3s,4r,5s)-2-[5,6-dichloro-2-(propan-2-ylamino)benzimidazol-1-yl]-5-(hydroxymethyl)oxolane-3,4-diol

12. 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1h-benzimidazole

13. 1263-w-94

14. Gw257406x

15. G1263

16. Maribavir [usan]

17. Unii-ptb4x93he1

18. Maribavir [usan:inn:ban]

19. Camvia(tm)

20. Camvia (tn)

21. Bw 1263w94

22. Maribavir [inn]

23. Maribavir (usan/inn)

24. Maribavir [who-dd]

25. Schembl791309

26. Chembl515408

27. Gtpl12049

28. Dtxsid60170091

29. Zinc3824412

30. Bw1263w94

31. 5,6-dichloro-2-(isopropylamino)-1-(beta-l-ribofuranosyl)-1h-benzimidazole

32. Akos015962194

33. Db06234

34. Gw 1263

35. Gw 257406x

36. 5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-1h-benzimidazol-2-amine

37. Ncgc00378559-03

38. Ac-22286

39. As-49903

40. Hy-16305

41. Vp-41263

42. D04859

43. O10059

44. Q6762512

45. Maribavir (1263w94, Benzimidazole D-ribose Derivative)

46. 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosylbenzimidazole

47. 5,6-dichloro-2-(isopropylamino)-1-(.beta.-l-ribofuranosyl)benzimidazole

48. 5,6-dichloro-2-isopropylamino-1-(beta-l-ribofuranosyl)-1h-benzimidazole

49. 1h-benzimidazol-2-amine, 5,6-dichloro-n-(1-methylethyl)-1-.beta.-l-ribofuranosyl-

50. 1h-benzimidazol-2-amine, 5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-

51. 5,6-dichloro-2-(isopropylamino)-1-.beta.-l-ribofuranosylbenzimidazole

52. 5,6-dichloro-n-(1-methylethyl)-1-.beta.-l-ribofuranosyl-1h-benzimidazol-2-amine

53. (2s,3s,4r,5s)-2-(5,6-dichloro-2-(isopropylamino)-1h-benzo[d]-imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

54. (2s,3s,4r,5s)-2-[5,6-dichloro-2-(isopropylamino)benzimidazol-1-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol

2.4 Create Date
2005-08-01
3 Chemical and Physical Properties
Molecular Weight 376.2 g/mol
Molecular Formula C15H19Cl2N3O4
XLogP32.2
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count6
Rotatable Bond Count4
Exact Mass375.0752615 g/mol
Monoisotopic Mass375.0752615 g/mol
Topological Polar Surface Area99.8 Ų
Heavy Atom Count24
Formal Charge0
Complexity447
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Maribavir is indicated for the treatment of adult and pediatric patients (weighing >35kg and at least 12 years old) with post-transplant cytomegalovirus (CMV) infection which is refractory to standard treatment with [ganciclovir], [valganciclovir], [cidofovir], or [foscarnet].


Cytomegaloviral disease


Treatment of cytomegalovirus (CMV) infection


5 Pharmacology and Biochemistry
5.1 Pharmacology

Maribavir exerts its antiviral efficacy via an alternative target as compared to traditional CMV antivirals and is thus useful in the treatment of CMV infections that have proven resistant to standard therapy. Maribavir should not be used concomitantly with ganciclovir or valganciclovir, as these molecules both require activation via CMV pUL97 in order to exert their antiviral effect. Taking them alongside maribavir - an inhibitor of this same kinase - will therefore significantly reduce their antiviral activity.


5.2 MeSH Pharmacological Classification

Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
MARIBAVIR
5.3.2 FDA UNII
PTB4X93HE1
5.3.3 Pharmacological Classes
Cytochrome P450 3A4 Inhibitors [MoA]; Cytomegalovirus pUL97 Kinase Inhibitor [EPC]; Cytomegalovirus pUL97 Kinase Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Breast Cancer Resistance Protein Inhibitors [MoA]
5.4 ATC Code

J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AX - Other antivirals

J05AX10 - Maribavir


5.5 Absorption, Distribution and Excretion

Absorption

Population pharmacokinetic modeling in patients receiving maribavir 400mg twice daily showed an AUC0-tau and Cmax of 128 g.h/mL and 17.2 g/mL, respectively. It has a median Tmax of one to three hours.


Route of Elimination

Maribavir is eliminated primarily via hepatic metabolism. Following the oral administration of radiolabeled maribavir, 61% of the dose was excreted in the urine (<2% as unchanged drug) and 14% was excreted in the feces (5.7% as unchanged drug).


Volume of Distribution

The mean apparent steady-state volume of distribution for maribavir was 27.3 L.


Clearance

In post-transplant patients, the mean oral clearance of maribavir was 2.85 L/h.


5.6 Metabolism/Metabolites

Maribavir is extensively metabolized following oral administration, primarily by CYP3A4 and, to a lesser extent, by CYP1A2. Its major circulating metabolite is VP 44469, an inactive N-dealkylated metabolite.


5.7 Biological Half-Life

In post-transplant patients, the mean half-life of elimination was 4.32 hours.


5.8 Mechanism of Action

Human cytomegalovirus (CMV) is a herpesvirus commonly causing infection in patients following stem cell or organ transplants. As with other herpesviruses, CMV tends to persist in the host and become reactivated under immunosuppressive conditions - patients requiring multiple immunosuppressive medications to combat transplant rejection are thus at a much higher risk of developing serious CMV infections. Maribavir belongs to a class of anti-cytomegalovirus antivirals called benzimidazole ribosides. It competitively inhibits the human CMV pUL97 viral protein kinase, which results in viable but severely defective viruses upon replication, although the reasons for this remain poorly defined. In addition, maribavir also inhibits viral release from the nucleus to the cytoplasm by inhibiting pUL97-dependent phosphorylation of the nuclear lamina component lamin A/C, although the extent to which this activity contributes to its antiviral efficacy is unclear.


Listed Suppliers

read-more
read-more

01

arrow
PharmaVenue
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Maribavir

About the Company :

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product ...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

PharmaVenue
Not Confirmed
arrow
arrow
PharmaVenue
Not Confirmed

Maribavir

About the Company : Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its ex...

Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its excellent research & development and aggressive growth strategies. Our 32 US DMFs and 9 CEPs in a short span attest to our R&D excellence. Maithri's manufacturing facility is located in Hyderabad. This facility is audited and approved by the US FDA. In addition, our facility is certified according to the standards of DCGI, WHO GMP, and ISO 9001:2015 We have a portfolio of 65 products and are continually expanding.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674498600,"product":"MARIBAVIR FORM VI","address":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST","city":"MUMBAI,MAHARASHTRA","supplier":"SANDOZ B2B","supplierCountry":"AUSTRIA","foreign_port":"NA","customer":"NOVARTIS PHARMACEUTICALS CORPORATION","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"12","unit":"GMS","unitRateFc":"10","totalValueFC":"131.3","currency":"EUR","unitRateINR":"894.5","date":"24-Jan-2023","totalValueINR":"10734","totalValueInUsd":"131.3","indian_port":"HYDERABAD AIR","hs_no":"29349990","bill_no":"4337367","productDescription":"API","marketType":"REGULATED MARKET","country":"AUSTRIA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"INSPIRE BKC PART OF 601 AND 701,BA NDRAKURLA COMPLEX BANDRA EAST"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703183400,"product":"MARIBAVIR, CAS NO. 176161-24-3, BATCH NO. DMMR202312001","address":"ACME PLAZA, ANDHERI KURLA ROAD,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHIJIAZHUANG DINGMIN PHARMACEUTICAL","supplierCountry":"CHINA","foreign_port":"BEIJING","customer":"SUN PHARMACEUTICAL INDUSTRIES LIMITED","customerCountry":"INDIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"7800","totalValueFC":"7852.2","currency":"USD","unitRateINR":"653640","date":"22-Dec-2023","totalValueINR":"653640","totalValueInUsd":"7852.2","indian_port":"Delhi Air","hs_no":"29349990","bill_no":"9366254","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BEIJING","supplierAddress":"SCIENCES CO., LTD.HONGSAM PLAZA BUILDING#A ROOM 1218,YUHUA DISTRICT,NO.52 ZHAIYINGSOUTH STREET SHIJIAZH CHINA","customerAddress":"ACME PLAZA, ANDHERI KURLA ROAD,"}]
24-Jan-2023
22-Dec-2023
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

MARIBAVIR

US Patent Number : 11684632

Drug Substance Claim :

Drug Product Claim :

Application Number : 215596

Patent Use Code : U-3650

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-01-04

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

US Exclusivities

read-more
read-more

01

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

MARIBAVIR

Exclusivity Code : NCE

Exclusivity Expiration Date : 2026-11-23

Application Number : 215596

Product Number : 1

Exclusivity Details :

blank

02

arrow
Pharma, Lab & Chemical Expo
Not Confirmed
arrow
Pharma, Lab & Chemical Expo
Not Confirmed

MARIBAVIR

Exclusivity Code : ODE-388

Exclusivity Expiration Date : 2028-11-23

Application Number : 215596

Product Number : 1

Exclusivity Details :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Maribavir Manufacturers

A Maribavir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Maribavir, including repackagers and relabelers. The FDA regulates Maribavir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Maribavir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Maribavir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Maribavir Suppliers

A Maribavir supplier is an individual or a company that provides Maribavir active pharmaceutical ingredient (API) or Maribavir finished formulations upon request. The Maribavir suppliers may include Maribavir API manufacturers, exporters, distributors and traders.

click here to find a list of Maribavir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Maribavir KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Maribavir Drug Master File in Korea (Maribavir KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Maribavir. The MFDS reviews the Maribavir KDMF as part of the drug registration process and uses the information provided in the Maribavir KDMF to evaluate the safety and efficacy of the drug.

After submitting a Maribavir KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Maribavir API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Maribavir suppliers with KDMF on PharmaCompass.

Maribavir NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Maribavir as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Maribavir API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Maribavir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Maribavir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Maribavir NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Maribavir suppliers with NDC on PharmaCompass.

Maribavir GMP

Maribavir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Maribavir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Maribavir GMP manufacturer or Maribavir GMP API supplier for your needs.

Maribavir CoA

A Maribavir CoA (Certificate of Analysis) is a formal document that attests to Maribavir's compliance with Maribavir specifications and serves as a tool for batch-level quality control.

Maribavir CoA mostly includes findings from lab analyses of a specific batch. For each Maribavir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Maribavir may be tested according to a variety of international standards, such as European Pharmacopoeia (Maribavir EP), Maribavir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Maribavir USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty